T. Rowe Price Investment Management, Inc. Apellis Pharmaceuticals, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 49,308 shares of APLS stock, worth $971,860. This represents 0.0% of its overall portfolio holdings.
Number of Shares
49,308
Previous 47,713
3.34%
Holding current value
$971,860
Previous $1.04 Million
18.2%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding APLS
# of Institutions
303Shares Held
135MCall Options Held
2.97MPut Options Held
623K-
Avoro Capital Advisors LLC New York, NY12.2MShares$241 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$234 Million17.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.2MShares$200 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.75MShares$192 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.98MShares$177 Million0.03% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.17B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...